More than three years have elapsed since the onset of the Coronavirus Disease 2019 (COVID-19) pandemic. Following the identification of this novel and intricate disease, clinicians and scientists worldwide have earnestly pursued innovative therapeutic approaches. In the early days of the pandemic, the lack of specific antiviral therapies for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) prompted the exploration of drugs approved for other indications, with the hope of reducing the high mortality associated with severe COVID-19 cases [1,2].
